If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRentokil Initial Regulatory News (RTO)

Share Price Information for Rentokil Initial (RTO)

Share Price is delayed by 15 minutes
Get Live Data
452.00    7.30 (1.64%)
Bid:
454.60
Ask:
454.80
Spread: 0.20 (0.044%)
Market Cap: £11.37b
RTO Live PriceLast checked at - London Stock Exchange

Intraday Rentokil Initial Share Chart

Q1 Trading Update

20 Apr 2023 07:00

RNS Number : 8256W
Rentokil Initial PLC
20 April 2023
 

20 April 2023

 

RENTOKIL INITIAL PLC

FIRST QUARTER TRADING UPDATE

STRONG MOMENTUM CONTINUED WITH ORGANIC GROWTH OF 6.7%

 

 

AER1

CER

 

Q1 2023

£m

Q1 2022

£m

Change

%

Q1 2023

£m

Q1 2022

£m

Change

%

 

Revenue

 

 

1,259

 

722

 

74.4%

 

1,240

 

754

 

64.5%

 

 

Trading in the year has started well, with reported Revenue up 64.5%, reflecting the benefit of M&A, including Terminix, and strong Organic Revenue2 growth of 6.7%. Including revenue from COVID disinfection business, Group organic growth was 5.9%. The performance has been underpinned by resilient demand and effective pricing, which has continued to offset inflationary pressures.

 

Regional Overview

 

North America delivered a good performance, with Organic Revenue growth of 4.9%. Strong momentum was sustained in Europe inc. LATAM, the Group's second largest region (+12.0% Organic Revenue), Asia & MENAT (+10.8% Organic Revenue) and Pacific (+7.5% Organic Revenue). Even with the anticipated reduction in COVID related medical waste services, the UK & Sub Saharan Africa region recorded 4.4% Organic Revenue growth.

 

Category Overview

 

Our Pest Control business delivered Organic Revenue growth of 6.4%. North America Pest Control recorded 4.9% Organic Revenue growth, driven by a strong start to the year of c.6.0% in pest control services for our commercial, residential, and termite customers. This growth was partially offset by the products distribution business, which has seen a slower start to the season contributed to by de-stocking across a number of major accounts and adverse weather conditions across some of our regional markets.

 

Our Hygiene & Wellbeing business, supported by continued good demand for washroom services, also performed well during the first quarter, with Organic Revenue up 5.5% (Revenue +6.2%). France Workwear continued its strong growth rates with Organic Revenue up by 17.3% (Revenue +17.3%) over the period.

 

M&A

 

Delivery of the Terminix integration plan has progressed well in the first quarter of the year and the cost synergy programme is on track to meet full year guidance.

 

The Group completed 15 additional bolt-on acquisitions in the first quarter - 12 in Pest Control and 3 in Hygiene & Wellbeing, with combined annualised revenues in the year prior to acquisition of c.£63m. This included the acquisition of RK Environmental/Comprehensive Food Safety, a specialist in pest management services and food safety audit consulting to the commercial food industry operating in 31 US states. RK had annualised revenues of c.$22m in the year prior to purchase, ranking #44 on the Pest Control Technology 2022 Top 100 list. We have built a substantial pipeline of high-quality opportunities and remain confident in our targeted spend of c.£250m in 2023.

 

In March 2023, Rentokil Initial was named as one of Britain's Most Admired Companies3 for the quality of its products and services.

 

Commenting on today's trading update, Andy Ransom, Chief Executive, said:

 

"I am delighted with the performance our colleagues delivered in Q1, which demonstrates the resilience of our compounding growth model and continued strategy execution. This performance, combined with further progress in our value-creating M&A programme led by the integration of Terminix, means we are well positioned for the remainder of the year. We reiterate our 2023 full year expectations."

 

 

Summary of financial performance (at CER)

 

Regional Performance

 

 

 

 

 

 

Revenue

Organic Revenue growth excluding disinfection

Organic Revenue growth including disinfection

Q1 2023 £m

Q1 2022 £m

 

Change

%

Q1

2023

%

Q1

2023

%

 

 

 

 

 

North America

745

320

132.9%

4.9%

4.8%

Pest Control

723

298

142.6%

4.9%

4.9%

Hygiene & Wellbeing

22

22

1.0%

4.2%

1.0%

 

 

 

 

 

Europe (inc LATAM)

254

211

20.4%

12.0%

10.5%

Pest Control

120

90

34.2%

11.2%

11.2%

Hygiene & Wellbeing

82

77

6.2%

9.9%

5.9%

France Workwear

52

44

17.3%

17.3%

17.3%

 

 

 

 

 

UK & Sub Saharan Africa

94

90

4.5%

4.4%

4.3%

Pest Control

50

45

11.0%

10.5%

10.5%

Hygiene & Wellbeing

44

45

(1.8%)

(1.7%)

(1.8%)

 

 

 

 

 

Asia & MENAT

84

77

9.5%

10.8%

4.2%

Pest Control

62

53

16.8%

11.1%

11.1%

Hygiene & Wellbeing

22

24

(7.0%)

9.5%

(11.6%)

 

 

 

 

 

Pacific

61

54

11.9%

7.5%

7.5%

Pest Control

29

24

21.7%

12.5%

12.5%

Hygiene & Wellbeing

32

30

4.1%

3.6%

3.5%

 

 

 

 

 

Central

2

2

4.7%

-

-

Total at CER

1,240

754

64.5%

6.7%

5.9%

Total at AER

1,259

722

74.4%

 

 

 

 

 

Category Performance

 

 

 

 

 

Revenue

Organic Revenue growth excluding disinfection

Organic Revenue growth including disinfection

Q1 2023 £m

Q1 2022 £m

 

Change

%

Q1

2023

%

Q1

2023

%

 

 

 

 

 

Pest Control

984

510

93.2%

6.4%

6.4%

Hygiene & Wellbeing

202

198

1.9%

5.5%

1.1%

France Workwear

52

44

17.3%

17.3%

17.3%

Central

2

2

4.7%

-

-

Total at CER

1,240

754

64.5%

6.7%

5.9%

Total at AER

1,259

722

74.4%

 

 

 

 

 

Enquiries:

 

Investors / Analysts: Peter Russell, Rentokil Initial plc, + 44 7795 166506

Media: Malcolm Padley, Rentokil Initial plc, +44 7788 978199

 

 

Notes

 

1AER - actual exchange rates; CER - constant 2022 exchange rates

 

2Organic Revenue growth represents the growth in Revenue excluding the effect of businesses acquired during the year and, unless stated otherwise, exclude COVID disinfection. Acquired businesses are included in organic measures in the year following acquisition, and the comparative period is adjusted to include an estimated full year performance for growth calculations (pro forma revenue). The Terminix acquisition is treated differently to other acquisitions for Organic Revenue growth purposes. The full pre-acquisition results of the Terminix business are included for the comparative period and Organic Revenue growth is calculated as the growth in Revenue compared to the comparative period.

 

3Britain's Most Admired Companies measures the reputation of more than 250 of Britain's largest companies across 28 industry sectors and it has been running since 1990. The survey is run by Echo Research with the support from academic partners, Coventry University.

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTMZGMDRLGGFZM
Date   Source Headline
3rd Oct 20222:36 pmRNSBlock listing Interim Review
30th Sep 202211:42 amRNSDirector Declaration
14th Sep 20225:55 pmRNSDirector/PDMR Shareholding
14th Sep 202212:21 pmRNSDirector/PDMR Shareholding
7th Sep 20222:38 pmRNSPublication of Circular-Prospectus & GM Notice
22nd Aug 20227:00 amRNSHolding(s) in Company
5th Aug 20222:02 pmRNSDirector/PDMR Shareholding
28th Jul 20227:00 amRNS2022 Interim Results
27th Jul 20229:54 amRNSDirector Declaration
18th Jul 20223:11 pmRNSHolding(s) in Company
15th Jul 20225:30 pmRNSHolding(s) in Company
15th Jul 202211:57 amRNSHolding(s) in Company
27th Jun 20222:27 pmRNSPost stabilisation notice - Rentokil Initial Plc
22nd Jun 20224:16 pmRNSHolding(s) in Company
21st Jun 20223:37 pmRNSDirector/PDMR Shareholding
20th Jun 20229:12 amRNSPre stabilisation notice - Rentokil Initial Plc
20th May 202210:20 amRNSDirector/PDMR Shareholding
12th May 20227:00 amRNSResult of AGM
21st Apr 20227:00 amRNSQ1 Trading Update
1st Apr 20227:00 amRNSBlock listing Interim Review
31st Mar 20226:15 pmRNSTotal Voting Rights
30th Mar 20229:44 amRNSAnnual Financial Report
29th Mar 20222:20 pmRNSDirector/PDMR Shareholding
25th Mar 20224:31 pmRNSDirector/PDMR Shareholding
15th Mar 20227:00 amRNSUpdate on Terminix acquisition
14th Mar 202211:00 amRNSAdditional Listing
3rd Mar 20227:00 amRNSFinal Results
2nd Mar 202210:29 amRNSDirector/PDMR Shareholding
28th Feb 20224:47 pmRNSHolding(s) in Company
22nd Dec 20215:38 pmRNSDirector/PDMR Shareholding
21st Dec 20214:09 pmRNSDirector/PDMR Shareholding
16th Dec 20217:00 amRNSFurther re Terminix Acqn S&P reaffirms BBB rating
15th Dec 20212:02 pmRNSDirector/PDMR Shareholding
14th Dec 20217:00 amRNSAcquisition of Terminix by Rentokil Initial plc
22nd Oct 202110:42 amRNSDirector Declaration
21st Oct 20217:00 amRNSQ3 Trading Update
1st Oct 202110:00 amRNSBlock listing Interim Review
28th Sep 20217:00 amRNSNotice of Capital Markets Day
17th Aug 20216:09 pmRNSDirector/PDMR Shareholding
12th Aug 20214:48 pmRNSDirector/PDMR Shareholding
29th Jul 20217:00 amRNSInterim Results
8th Jul 20217:00 amRNSNotice of termination of guarantee
11th Jun 20211:50 pmRNSNotice of Early Redemption
12th May 20216:03 pmRNSResult of AGM
22nd Apr 20217:00 amRNSQ1 Trading Update
7th Apr 20212:01 pmRNSDirector/PDMR Shareholding
1st Apr 20216:30 pmRNSDirector/PDMR Shareholding
1st Apr 202110:23 amRNSBlock listing Interim Review
1st Apr 202110:16 amRNSChange of Registered Office
31st Mar 20214:00 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.